NeoGenomics, Inc. Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Published: 2025-06-30 07:50:37 ET NEO

Published on 06/30/2025 at 07:50

NeoGenomics, Inc. announced the launch of PanTracer?? Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently.

PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings.

The assay builds on the company's tissue-based CGP platform, previously known as NeoComprehensive®? Solid Tumor. The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer.

The PanTracer Tissue +HRD offering includes BRCA mutation status and a genomic instability score--critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies. PanTracer Tissue and PanTracer Tissue + HumanD are part of NeoGenomics' broader portfolio of precision oncology solutions designed to improve patient outcomes through high-quality, guideline-aligned testing.

Revealed at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the continually expanding PanTracer portfolio reflects the company's dedicated focus on advancing diagnostic tools that support more informed, personalized care.